ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)-Reference-Cited by-同舟云学术

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

Published:2018-06 Issue: Volume:24 Page:S83-S94
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Drgona L.,Gudiol C.,Lanini S.,Salzberger B.,Ippolito G.,Mikulska M.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference76 articles.

1. ESCMID study group for infections in compromised hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction);Fernández-Ruiz;Clin Microbiol Infect,2018

2. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project;Carson;Cancer,2014

3. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system;Raisch;Expert Opin Drug Saf,2016

4. Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences;Berger;N Engl J Med,2005

5. Target therapy in hematological malignances: new monoclonal antibodies;Podhorecka;Int Sch Res Not,2014

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atypical Presentation of Invasive Aspergillosis during Treatment with Mogamulizumab;Journal of Fungi;2024-08-17

2. Targeted therapy for leukemia based on nanomaterials;Heliyon;2024-08

3. Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018–2021;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

4. Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma;Acta Haematologica;2024-04-24

5. Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients;Life;2024-03-15